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Abstract

TITLE: Substance Use Screening, Brief Intervention, and Referral to Treatment (SBIRT)
in Pregnant Women Living with Human Immunodeficiency Virus (HIV)

BACKGROUND: According to the 2018 National Survey on Drug Use and Health,
5.4%, 9.9%, and 11.1% of pregnant women reported use of illicit drugs, alcohol, and
tobacco, respectively, in the past month. In the same year, Centers for Disease Control
reported 19% of new HIV diagnoses were among women. Substance use in pregnant
women living with HIV increases risk of adverse outcomes for both mother and child
including neonatal viral transmission and obstetrical complications. Universal screening
for substance use during pregnancy identifies opportunities to implement interventions
which can improve maternal and infant health.

PURPOSE: The purpose of this project is to implement standardized, universal substance
use screening at a Mother Child Adolescent HIV Program’s specialized obstetrics and
gynecology clinic.

EVIDENCE BASED INTERVENTIONS: SBIRT is an evidence-based, comprehensive,
public health approach to delivery of early intervention which identifies, reduces, and
prevents problematic use of alcohol and illicit drugs. Utilizing a multidisciplinary, teambased approach, we plan to implement National Institute on Drug Abuse (NIDA) Quick
Screen, a validated substance use screening tool recommended by American College of
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Obstetricians and Gynecologists. Following screening, moderate and high-risk patients
will receive a brief intervention and referral to substance use treatment.

EVALUATION/ RESULTS: During a 12-month period, SBIRT was universally applied
to 15 pregnant women of a Mother Child Adolescent HIV clinic. The women were
screened using NIDA Quick Screen and based on their responses, were stratified into risk
categories for intervention if deemed necessary. Of 15 women screened, two were
deemed moderate risk and none required referral. Prior to implementation of universal
screening there was no standardized approach, which means there is no prior data for
comparison.
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Substance Use Screening, Brief Intervention, and Referral to Treatment (SBIRT) in
Pregnant Women Living with HIV
Description of Clinical Problem
Substance use of any kind during pregnancy can lead to a myriad of social and
medical problems for women and babies (World Health Organization, n.d.). Recent data
show women are at highest risk of developing a substance use disorder during their
reproductive years, which indicates women who are pregnant or about to be pregnant are
at an increased risk (Forray, 2016). Data from the 2019 National Survey on Drug Use and
Health (NSDUH) indicated use of marijuana has increased in all women surveyed
between 2018 and 2019 but has also increased in pregnant women who were screened
(NSDUH, 2020). The same survey found tobacco is the most common substance used in
pregnancy at 9.6%, followed by alcohol at 9.5%, cannabis at 5.4%, and illicit drugs at
5.8% (NSDUH, 2020). Data indicate substance use in pregnancy is a critical public health
concern and women need to be efficiently screened.
Perhaps one of the most vulnerable populations of women in regard to substance
use are those living with HIV. Pregnancy is an extremely vulnerable time for women
living with HIV. According to Center for Disease Control (Gonzalez et al., 2012), many
women are diagnosed with HIV during their pregnancy, and are simultaneously
struggling to cope with the new diagnosis, associated stigma, and potential impacts on
interpersonal relationships. Other women reengage in HIV care because of a current
pregnancy (Gonzalez et al., 2012). Substance use creates a significant challenge for
women living with HIV because it contributes to low levels of engagement in treatment
and poor medication adherence. Those who use substances intravenously are more than
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twice as likely to stop antiretroviral therapy compared to those who do not and, in
general, have a lower rate of viral suppression than those who do not use substances
(Dawson-Rose et al., 2017). Furthermore, women living with HIV who are using
substances have suboptimal adherence of their antiretroviral medications (Zhang et al.,
2017). As most women strive to have a healthy baby, prenatal care presents a unique
opportunity to address HIV, behavioral health/substance use issues, support retention in
HIV care, and to optimize viral suppression (Melo et al., 2014). Women are also at high
risk of falling out of HIV care following delivery, and effective behavioral health and
substance use interventions have been shown to improve and support engagement in HIV
primary care and treatment (Gonzalez et al., 2012).
Substance use during pregnancy is as common as many medical conditions
routinely screened for in pregnancy, including cystic fibrosis, anemia, perinatal
depression, gestational diabetes, or preeclampsia (Wright et al., 2016). Not only is
substance use during pregnancy common, it leads to costly and adverse outcomes
including, but not limited to, preterm deliveries, low birthweight, birth defects,
miscarriages, antepartum hemorrhage, and lengthy antepartum and NICU admissions
(Wright et al., 2016). Due to increased rates of perinatal opioid use disorder, there has
been a 3-fold increase in neonatal abstinence syndrome (NAS). NAS treatment requires
weeks to months in the hospital depending on severity of symptoms (Wright et al., 2016).
Some long-term effects on both mother and infant can be lifelong and require routine
medical follow up.
Several governmental and professional organizations offer evidence-based
guidelines to minimize potential public health impacts of substance use in pregnant
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women living with HIV. According to the CDC, universal screening for substance use
during pregnancy identifies opportunities to implement interventions which improve
maternal and infant health (Wright et al., 2016). United States Preventive Services Task
Force (USPSTF) and American Congress of Obstetricians and Gynecologists (ACOG)
recommend universal screening (S) for substance use during pregnancy, brief
intervention (BI), and referral to treatment (RT) for those who screen positive (American
Congress of Obstetricians and Gynecologists, 2017; Chasnoff et al., 1990). Screening,
Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based intervention
designed to identify, reduce, and prevent problematic use of alcohol and drugs. SBIRT
allows for tailored services based on risk level reference. Addressing substance use helps
improve medication adherence, viral suppression of the mother, and improve postpartum
retention in HIV care reference.
Description of Project
The Maternal Child and Adolescent HIV Program (MCAP) at a large medical
center serves women and children living with HIV. Its mission is to provide family
centered and comprehensive HIV care to women, children, and adolescents. Using a
multidisciplinary team of HIV specialists, the clinic provides medical care, patient
education, counseling, and case management. The paper will not identify the name of the
medical center to protect the identities of those it serves. The MCAP program has a
specialized OB/GYN clinic for pregnant and postpartum women living with HIV. This
specialized clinic is composed of an OBGYN, nurse practitioner, and licensed social
workers.
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Historically, clinic substance use screening and assessment was composed of
provider specific questions about substance use. Lack of an evidence-based substance use
policy resulted in large variation in substance use screening and assessment practices.
Therefore, the clinic sought to enhance services currently provided to pregnant women
living with HIV by implementing more effective universal screening, brief intervention,
and referral to treatment.
The new protocol proposed involved the same social worker conducting the
screening during a patient’s prenatal intake appointment with the OBGYN. For the
project to be successful, the company selected a new assessment tool. The NIDA Quick
Screen is a questionnaire of three open ended questions related to drug, alcohol, and
tobacco use (National Institute on Drug Abuse, 2012). This DNP student chose the NIDA
Quick Screen because providers are familiar with it because it is used in other facilities of
the hospital with success. If the patient screens negative for substance use, then screening
is finished. If a patient screens positive for substance use, then screening expands into
NIDA Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) and asks
specifics about lifetime and recent substance use.
This approach allowed for women to be stratified into risk zones based on their
pattern of use and by provider discretion. Per SBIRT guidelines, a woman who scores 0–
3 is considered low risk (no past usage of alcohol, tobacco, or other drugs, or low levels
of use were stopped prior or immediately after discovery of pregnancy), has continued
the offered support and remained abstinent from substances (Wright et al., 2016). The
women score deemed moderate risk (4–26), which are those who have low level of usage
during pregnancy or who have used high quantities of substances in their pregnancy, are
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given a brief intervention, have motivational interviewing performed and will have
frequent follow ups with their provider (Wright et al., 2016). Women identified in the
high-risk category (>27), who are those who are actively using illicit substances in their
pregnancy and meet criteria for Substance Use Disorder (SUD), are referred to
specialized treatment.
Literature Review
The author conducted a literature review to inform this project. The initial
literature search involved CINAHL and PubMed databases. Keywords used for this
search included pregnant woman, expecting mother, SBIRT, substance use, HIV, brief
intervention, reproductive health, and screening. SBIRT research specific to women
living with HIV is limited. The following section reviews literature on SBIRT efficacy.
Research from Hostage et al. (2020) demonstrated SBIRT offers a standardized
approach showing screening gaps and areas for improvement. Martino et al. (2018)
conducted a randomized control trial (RCT) between September 2011 and January 2015
and randomly placed women using nicotine, alcohol, illicit drugs, or misusing
prescription medications into two groups. One group received the standard of care and
the other received electronic SBIRT. The researchers performed assessments of the two
groups at one, three, and six months after a baseline was established. Implementing
SBIRT decreased days of primary substance use in women and did not result in more
treatment than those who received usual care (Martino et al., 2018). The implication for
practice is an SBIRT tool facilitates substance use documentation and can get targeted
treatment to patients in need to decrease their days of substance use.
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In a cross-site evaluation of 11 sites and more than one million patients, Babor et
al. (2017) employed a multimethod evaluation design to evaluate processes, cost, and
outcome of implementation of SBIRT. Pre and post differences were clinically and
statistically significant, showing a decrease in substance use and positive outcomes, so
67% of sites continued with SBIRT after grant funding ended (Babor et al., 2017).
Notably, SBIRT also contributed to treatment equity, efficiency, and cost effectiveness.
A two-arm RCT from Dawson-Rose et al. (2017) examined effects of a
computerized self-administered SBIRT intervention compared to a provider administered
SBIRT intervention in an HIV primary clinic. Dawson-Rose et al. (2017) scored patients
using the World Health Organization’s Alcohol, Smoking and Substance Involvement
Screening Test to assess Specific Substance Involvement Scores (SSIS) before
intervention and then at one, three, and six months. Based on those scores, patients were
stratified into low, moderate, or high- risk categories. The study concluded substance use
in the patient population was near universal with moderate risk being the most common
category (Dawson-Rose et al., 2017). Among patients who received in-person SBIRT
invention, SSIS decreased among moderate-high risk baseline participants but increased
in the baseline low risk group over six months (Dawson-Rose et al., 2017). The
implication for practice is there might need to be more interventions to help support low
risk patients to maintain their healthy behaviors and engagement.
In a meta-analysis of 13 RCTs from Glass et al. (2015), there was no evidence
brief intervention for alcohol use was effective in increased use of referral care. Though
this meta-analysis did not find SBIRT to be effective, it did show patients with higher
severity of substance use and those recruited from more acute settings were more likely
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to use referral services than those with lower severity scores (Glass et al., 2015). None of
the studies analyzed an association between clinical outcomes and treatment use. The
RCTs included in this meta-analysis were not designed with the primary focus on referral
to treatment. This means there was a lack of data to evaluate whether or not referral and
receipt of treatment improved clinical outcomes in brief intervention recipients. Future
researchers need to include are clinical trials focusing on referral to treatment as the
primary outcome and sufficiently track referral processes.
Another study from Tassiopoulos et al. (2010) looked at self-reporting of
substance use in a cohort of women living with HIV compared to meconium results. The
study evaluated substance use in pregnancy in Surveillance Monitoring for ART
Toxicities Study in HIV-uninfected Children (SMARTT), a group of 22 clinic sites in 12
states. Mothers were enrolled after 23 weeks of gestation through 72 hours after delivery.
If an infant was found to be HIV infected, the dyad was discontinued from the study and
referred to HIV care. Enrolled mothers completed a substance use questionnaire and
meconium was collected from their infants. Results found self-reported substance use
was reliable when compared to meconium. The implication for practice is this patient
demographic can be relied upon with their self-disclosure about substance use. In fact,
self-reporting is an even more valuable tool for assessing substance use than meconium
collection due to substances such as alcohol and tobacco not being detectable in
meconium (Tassiopoulos et al., 2010). The other notable finding is use of illicit
substances is low, but alcohol and tobacco exposure is relatively common in pregnancy.
Research on effects of recreational drug use on medication adherence among
women is scant. A multicenter RCT from Zhang et al. (2017) assessed adherence of
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taking a single tablet antiretroviral (STR) versus multi-tablet antiretroviral regimen
(MTR) in HIV+ women who use substances. The study found substance use other than
marijuana only was associated with suboptimal medication adherence in both STR and
MTR users and marijuana use was associated with suboptimum STR adherence (Zhang et
al., 2017). This is relevant for practice because substance use was found to be connected
to issues with medication adherence in general. Moreover, marijuana specifically impairs
STR adherence. This finding significantly impacts patient outcomes, particularly in states
with legalized recreational marijuana use.
Evidence Based Practice Model
This Evidence Based Project (EBP) was framed by the IOWA model. The IOWA
model is specifically engineered toward evidenced based change inclusive of the entire
medical team including physicians, nurses, and allied healthcare providers.
Interdisciplinary teamwork is already a value of the MCAP clinic because they rely on it
to manage and optimize their patients’ healthcare. Additionally, the project uses one
social worker to screen patients, but other medical providers need to be kept informed on
the status of screening and whether or not patients are referred to further treatment. As
discussed by Hostage et al. (2020), SBIRT relies on interdisciplinary approaches to
decrease days of primary substance use.
The project implemented evidence-based practice to identify HIV positive
pregnant mothers who are at moderate to high risk for substance use with a universal
screening tool. Before implementation, there was no standardized approach or
questionnaire to identify women at risk for substance use in their pregnancy.
Consequently, there was a risk of substance-using patients who were not being identified.
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Lack of identification increases risk of ARV adherence which further increases risk of
prenatal care adherence which further increases the risk of prenatal care adherence. This
ultimately jeopardizes their adherence to prenatal care thereby risking both maternal and
newborn health. One of the strengths of the IOWA model is its use of feedback loops
(Doody & Doody, 2013), which allow plenty of opportunities for team-based feedback
and interdisciplinary feedback. Feedback loops are essential in determining effectiveness
and ease of proposed changes for involved personnel. Additionally, this model has been
shown to be very effective in development of curriculums for Quality Improvement (QI)
projects, EBP research and training/education, and showing positive effect in
improvement projects which is the overall goal of evidence-based projects such as this.
Several times over the course of the project, a DNP student was in contact with the
screening social worker to inquire about progress, any suggestions for project
improvement, and to offer moral support. There were also two opportunities for other
members of the clinic team (e.g., physician, nurse practitioner, other licensed social
workers) to offer feedback to this student. The author presented the evidence for change
prior to the implementation of the project and then disseminated the data at the end. Both
opportunities led to brainstorming sessions on how to improve the project moving
forward.
Practice Change Process
This evidence-based project was initiated based on identified need of the
Maternal, Child, and Adolescent HIV clinic in the summer of 2019. The MCAP clinic’s
lead social worker performed a needs assessment and received a small grant to implement
SBIRT to improve substance use screening process for patients. The lead social worker
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involved the DNP student and her faculty advisor to choose a validated screening tool
and develop protocols for use. The author chose the National Institute Drug Abuse
(NIDA) Quick Screen as the validated screening tool due to success and familiarity in
other facilities. The designated social worker gave patients with a positive screening on
the initial tool were given NIDA-Modified ASSIST to continue the screening. Modified
ASSIST looks at lifetime substance use and scored patients in one of three categories
based on their assessed risk level. The author chose the IOWA model as the framework
for the project. The hallmarks of the IOWA model are interdisciplinary and feedback
foci. Because this project relied heavily on teamwork and constant communication
between MCAP providers and this student, it seemed an appropriate model.
The author presented the clinical benefits of implementing SBIRT to the clinic’s
social workers, physicians, and nurse practitioner to receive their support and inform
them of upcoming changes. The project then obtained approval from the hospital’s
Institutional Review Board (IRB) and university-affiliated IRB prior to implementation.
The clinic designated a specific social worker to perform SBIRT on all the clinic’s
patients during their initial prenatal appointment. Implementation began in January 2020
and continued through January 2021. At three, six, and nine months I asked for feedback
from designated social workers to make any changes or adjustments based on her
feedback. The feedback centered on trying to gain access and information from referral
sites. Due to being overwhelmed with impacts of COVID-19, referral sites were requiring
contact from prospective patients and not the clinic. The DNP student attempted contact
with referral sites also but was unsuccessful. The author collected data in January 2021
and a stakeholder presentation was performed in March 2021 to disseminate results.
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Data Analysis
Between January 2020 and January 2021, all 15 of the clinic’s pregnant patients
were included in screening. They ranged from 21–38 years old. Variables assessed
included age, screening results, and whether or not they were referred to specialized
treatment if deemed high risk. No patients were deemed high risk, 20% (three of 15) were
moderate risk, and 80% were assessed as low risk (see Figure 1).
Figure 1
Risk Assessment

The Modified ASSIST identified four patients who used alcohol during their
pregnancies and three patients who smoked cigarettes (see Figure 2). Social Worker
documentation clarified these patients had stopped smoking upon discovering they were
pregnant but screened positive due to NIDA assist’s assessment of recent and lifetime
use. Two patients indicated methamphetamine use and one was using marijuana with no
intention of quitting. Patients who admitted to methamphetamine and marijuana use
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scored as moderate risk and ultimately scored under the threshold for referral to
treatment.
Figure 2
Substance Use Scores During Pregnancy

Cost-Benefit Analysis
The financial benefit of SBIRT implementation is mainly looked at in terms of
cost avoidance. By avoiding consequences of substance use, there is a cost savings for
patients and hospital systems alike. One meta-analysis considered costs of HIV
medication nonadherence and found patients spent anywhere between $1,300 and $2,000
per month on nonadherent treatment depending on their viral load, which translates to a
range of $16,957–$30,068 per year (Gonzalez et al., 2011). That is not an insignificant
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amount to most people, let alone when raising children. Another study showed applying
SBIRT was associated with a general reduction in Medicaid costs per member, per month
of $366 for those who received a referral and $542 per member, per month for those who
received only a brief intervention (Estee et al., 2010). The same study also showed
SBIRT has potential to reduce resource consumption among Medicaid patients in
hospitals.
Other prospective costs prudent to avoid are those associated with maternal and
neonatal complications. Between 2006 and 2012, rates of maternal and neonatal
hospitalizations related to substance use increased 33% and 71%, respectively (Agency
for Healthcare Research and Quality, 2015). It is safe to assume rates have steadily
increased in the near decade since. The same study showed costs of neonatal stays
increased by 135% over that time frame from $253.4 million to $594.6 million and
cumulatively to $944 million for mothers and neonates (Agency for Healthcare Research
and Quality, 2015). Of maternal hospital stays related to substance use in 2012, one-third
involved marijuana use and one-fourth involved opioids (Agency for Healthcare
Research and Quality, 2015). This supports use of a validated screening tool to identify
which substance is being used and how frequently to treat patients properly and avoid
unnecessary and costly complications.
The benefit of implementing SBIRT is not solely about cost avoidance. American
Medical Association (AMA) has approved several billing codes for SBIRT
reimbursement. Reimbursement ranges from $24–$48 for 15 min screenings (American
Society of Addiction Medicine, 2017). The screening tool is free to use and, other than
one hour for staff training offered during lunch and dedicating a social worker to
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administering screenings, there is no cost to continue with SBIRT once implemented.
Overall, it is a cost-effective way to improve maternal and neonatal outcomes.
Discussion, Challenges, and Implications
This section will review discussion, challenges and implications of this project.
There were significant challenges to implementation of this project. There were
significant challenges to implementation of the project, such as the global pandemic. We
did not expect issues such as remote versus in person assessments, cannabis use, COVID19 impact on referral sites, and comfort level of IRB presented issues. The following
section will address each issue.
The first and most notable difficulty was the COVID-19 global pandemic. In
March 2020, the clinic moved to a telemedicine platform. The social worker found the
change from screening a patient in-person to over phone or Zoom hampered ability to
form trust and patients did not fully disclose their substance use. In one instance, the
social worker had a patient’s chart and substance use history in front of her while
conducting the screening and was aware the patient was not being honest with her
answers. However, the social worker expressed in person she is able to use eye contact,
therapeutic communication, and other techniques to encourage a patient to be open.
There were other implications to remote screening. For some patients, having
internet access or a phone is cost prohibitive, which can make telemedicine inequitable.
Many clinic patients have less access to resources and have to rely on library computers
or public hotspots for internet connectivity, which is obviously not conducive for
telemedicine clinical appointments (Kronenfield & Penedo, 2020). Conducting a
substance use screening in an office greatly reduces risk of confidentiality being
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compromised. Additionally, patients may be impacted by attending telemedicine visits at
home with children or other family members present.
Another unseen complication of the global pandemic was impact on referral sites.
Clinic staff has historically had difficulties communicating with referral ties prior to
COVID-19, but sites became even less communicative after March 2020, likely due to an
increase in volume for need in services from patients. Researchers and academics have
already been discussing how COVID-19 has caused an increase in substance use and
surged interest in treatment (Abramson, 2021). Patients were also impacted and voiced
frustration about lack of returned phone calls and inquiries. No patients screened during
this project required referral to treatment, but it is a complication deserving consideration
and a strategy. Lack of communication is definitely problematic because, even prior to
COVID-19, referral sites were limited to offering intakes on certain days of the month.
Limited number of possible days for an intake can be difficult to plan around for women
with children in traditional situations. However, delayed communication presents an even
bigger challenge for mothers if sites no longer offer childcare due to COVID-19
precautions and childcare needs to be arranged quickly.
Screening for cannabis use also posed an interesting challenge. In California,
cannabis is a legal substance, but it has not been federally decriminalized. This presents
another difficulty because screening tools do not account for illicit substances and require
a separate question. However, not following exact verbiage of a screening tool as directed
can invalidate results. Proper and accurate assessment of marijuana use is important in
this patient population because research is clearly showing an increase in use. The
Substance Abuse and Mental Health Services Administration (SAMHSA) 2019 survey of
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substance use in the past month among pregnant women showed marijuana was the only
substance to have a clear increase in use from 2018 to 2019 (2020). Results also showed
daily or near daily marijuana use among nonpregnant women increased by 4.4%, from
2.2 million to 2.7 million women, and in pregnant women from 35,000 to 36,000 women
(SAMHSA, 2020). Women in their reproductive years are at high risk of using
substances and data presented by SAMHSA not only corroborates that but shows which
substances are trending upward.
No patients endorsing marijuana scored high enough for referral. However, in our
final feedback session, clinic staff discussed how patients who endorsed cannabis use
were often referred to Child Protective Services. These referrals caused some
disconcertion between both staff and patients because marijuana use has become more
commonplace, so individuals are viewing it less as an illicit drug and more as a natural
alternative to pharmaceuticals. Many patients were unaware disclosing their cannabis use
would trigger a CPS referral. Importantly, there is not a specific protocol pertaining to
cannabis use and CPS referrals at this facility. California also does not have a clear policy
about CPS referral for prenatal marijuana use. Additionally, the lead OB/GYN of the
clinic does not consider marijuana to be as concerning as other illicit drugs and he does
not routinely follow up on cannabis use in his patients.
The project highlighted this wide variation in clinical practice and could be
followed up on by a future student. Although more research needs to be done about
consequences of cannabis use in pregnancy, current meta-analyses have linked prenatal
cannabis use to low birth weight and preterm labor (Zhang et al., 2017). Potential impacts
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on neurocognitive and behavioral problems are unknown although several researchers
have pointed toward deleterious sequala (Jaques et al., 2014).
Another challenge involved the organization’s Human Research Protections
Program and IRB. Given how vulnerable this population is, IRB was very rigorous in
ensuring patient’s protected information stayed confidential. Initially given “exempt”
status, the clinic supervisor requested IRB was made aware the DNP student was no
longer an employee of the facility to see if this was still acceptable. Several IRB
administrators were unfamiliar with EBP projects and thus unsure whether or not we
were conducting research. To ensure IRB administrators were comfortable, we were only
given deidentified variables of age, SBIRT score, and whether or not the patient was
referred for further treatment.
A limitation to analyzing project outcomes was the previous screening system
was provider specific and not universal. Thus, there was no pre data to compare findings.
In addition to a very small sample size (which does not matter with EBP), data collected
were much more limited to original outcome variables, birth outcomes, postpartum
follow up SBIRT scores, and viral loads.
In conclusion, substance use has been shown to be a consistent barrier to HIV
medication adherence. It is also attributed to costly and deadly maternal and neonatal
complications and hospitalizations which have become more expensive over time.
Implementing SBIRT to standardize treatment of pregnant women living with HIV is a
cost effective, efficient, and evidence-based method to ensure substance use is properly
assessed and treated.

SBIRT in Pregnant Women with HIV

24
References

Abramson, A. (2021, March 1). Substance use during the pandemic. American
Psychological Association. https://www.apa.org/monitor/2021/03/substance-usepandemic
Agency for Healthcare Research and Quality. (2015, July). Neonatal and Maternal
Hospital Stays Related to Substance Use 2006–2012 (Statistical Brief #193).
https://hcup-us.ahrq.gov/reports/statbriefs/sb193-Neonatal-MaternalHospitalizations-Substance-Use.pdf
American Congress of Obstetricians and Gynecologists. (2017). Committee opinion no.
711: Opioid use and opioid use disorder in pregnancy. Obstetrics &
Gynecology, 130(2), 81–94. https://doi.org/10.1097/AOG.0000000000002235
American Society of Addiction Medicine. (2017, February 17). Reimbursement for
SBIRT. ASAM. https://www.asam.org/docs/default-source/education-docs/sbirtreimbursement-all-payer-overview_0220177fa32b9472bc604ca5b7ff000030b21a.pdf?sfvrsn=f41f4bc2_0
Babor, T., Del Boca, F., & Bray, J. W. (2017, January 10). Screening, brief intervention
and referral to treatment: Implications of SAMHSA's SBIRT initiative for
substance abuse policy and practice. Society for the Study of Addiction, 112(S2),
110–117. https://doi.org/10.1111/add.13675
Center for Disease Control (CDC). (2021, April 8). HIV and Pregnant Women, Infants,
and Children. Centers for Disease Control and Prevention.
https://www.cdc.gov/hiv/group/gender/pregnantwomen/index.html

SBIRT in Pregnant Women with HIV

25

Chasnoff, I. J., Landress, H. J., & Barrett, M. E. (1990, April 26). The prevalence of
illicit-drug or alcohol use during pregnancy and discrepancies in mandatory
reporting in Pinellas County, Florida. The New England Journal of Medicine,
(322), 1202–1206. https://doi.org/10.1056/NEJM199004263221706
Dawson-Rose, C., Draughon, J. E., Cuca, Y., Zepf, R., Huang, E., Cooper, B. A., & Lum,
P. J. (2017). Changes in specific substance involvement scores among SBIRT
recipients in an HIV primary care setting. Addiction Science & Clinical Practice,
12(1), 1–11. https://doi.org/10.1186/s13722-017-0101-1
Doody, C. M., & Doody, O. (2013). Introducing evidence into nursing practice: Using the
IOWA model. British Journal of Nursing, 20(11), 661–664.
https://doi.org/10.12968/bjon.2011.20.11.661
Estee, S., Wickizer, T., He, L., Shah, M. F., & Mancuso, D. (2010). Evaluation of the
Washington state screening, brief intervention, and referral to treatment project.
Medical Care, 48(1), 18–24. https://doi.org/10.1097/mlr.0b013e3181bd498f
Forray, A. (2016). Substance use during pregnancy. F1000Res, 5(F1000 Faculty Rev),
1–8. https://doi.org/10.12688/f1000research.7645.1
Glass, J. E., Hamilton, A. M., Powell, B. J., Perron, B. E., Brown, R. T., & Ilgen, M. A.
(2015). Specialty substance use disorder services following brief alcohol
intervention: A meta-analysis of randomized controlled trials. Addiction, 110(9),
1404–1415. https://doi.org/10.1111/add.12950
Gonzalez, A., Mimiaga, M. J., Israel, J., Andres Bedoya, C., & Safren, S. A. (2012).
Substance use Predictors of poor medication adherence: The role of substance use

SBIRT in Pregnant Women with HIV

26

coping among HIV-infected patients in opioid dependence treatment. AIDS and
Behavior, 17(1), 168–173. https://doi.org/10.1007/s10461-012-0319-6
Gonzalez, J. S., Batchelder, A. W., Psaros, C., & Safren, S. A. (2011). Depression and
HIV/AIDS treatment nonadherence: A review and meta-analysis. JAIDS Journal
of Acquired Immune Deficiency Syndromes, 58(2), 181–187.
https://doi.org/10.1097/qai.0b013e31822d490a
Hostage, J. C., Brock, J., Craig, W., & Sepulveda, D. (2020). Integrating screening, brief
intervention and referral to treatment (SBIRT) for substance use into prenatal
care. Maternal and Child Health Journal, 24(4), 412–418.
https://doi.org/10.1007/s10995-020-02892-9
Indiana University. (2013, December 20). SBIRT Can Help. SBIRT@IUSM.
http://iusbirt.org/course1/sbirt-can-help/
Jaques, S., Kingsbury, A., Henshcke, P., & Chomchai, C. (2014, June). Cannabis, the
pregnant woman and her child: Weeding out the myths. Journal of Perinatology,
34(6), 417–424. https://doi.org/10.1038/jp.2013.180
Kronenfield, J., & Penedo, F. (2020). Novel coronavirus (COVID-19): Telemedicine and
remote care delivery in a time of medical crisis, implementation, and challenges.
Translational Behavioral Medicine, 11(2), 659–663.
https://doi.org/10.1093/tbm/ibaa105
Martino, S., Ondersma, S. J., Forray, A., & Olmstead, T. (2018). A randomized
controlled trial of screening and brief interventions for substance misuse in
reproductive health. American Journal of Obstetrics and Gynecology, 218(3),
322. https://doi.org/10.1016/j.ajog.2017.12.005

SBIRT in Pregnant Women with HIV

27

Melo, V. H., Botelho, A. P. M., Maia, M. M. M., Correa Júnior, M. D., & Pinto, J. A.
(2014). Illicit drug use by pregnant women infected with HIV. Revista Brasileira
de Ginecologia e Obstetrícia, 36(12), 555–561. https://doi.org/10.1590/so100720320140005155
National Institute on Drug Abuse. (2012, March). The NIDA Quick Screen. NIDA.
https://www.drugabuse.gov/sites/default/files/pdf/nmassist.pdf
Substance Abuse and Mental Health Services Administration (SAMHSA). (2020). The
National Survey on Drug Use and Health: 2019.
https://www.samhsa.gov/data/sites/default/files/reports/rpt29392/AssistantSecretary-nsduh2019_presentation/Assistant-Secretarynsduh2019_presentation.pdf
Tassiopoulos, K., Read, J. S., Brogly, S., Rich, K., Lester, B., Spector, S. A., Yogev, R.,
& Seage, G. R. (2010). Substance use in HIV-infected women during pregnancy:
Self-report versus meconium analysis. AIDS and Behavior, 14(6), 1269–1278.
https://doi.org/10.1007/s10461-010-9705-0
World Health Organization. (n.d.). Management of Substance Abuse.
https://www.who.int/substance_abuse/activities/pregnancy_substance_use/en/
Wright, T. E., Terplan, M., & Ondersma, S. J. (2016). The role of screening, brief
intervention, and referral to treatment in the perinatal period. American Journal of
Obstetrics and Gynecology, 215(5), 539–547.
https://doi.org/10.1016/j.ajog.2016.06.038
Zhang, Y., Wilson, T. E., Adedimeji, A., Merenstein, D., Milam, J., Cohen, J., Cohen,
M., & Golub, E. T. (2017). The impact of substance use on adherence to

SBIRT in Pregnant Women with HIV

28

antiretroviral therapy among HIV-infected women in the United States. AIDS and
Behavior, 22(3), 896–908. https://doi.org/10.1007/s10461-017-1808-4

29

